Compare PRVA & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRVA | APGE |
|---|---|---|
| Founded | 2007 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 4.7B |
| IPO Year | 2021 | 2023 |
| Metric | PRVA | APGE |
|---|---|---|
| Price | $22.35 | $82.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $31.17 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 994.8K | 557.3K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.64 | N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $2,122,842,000.00 | N/A |
| Revenue This Year | $18.19 | N/A |
| Revenue Next Year | $10.72 | N/A |
| P/E Ratio | $1,139.00 | ★ N/A |
| Revenue Growth | ★ 22.26 | N/A |
| 52 Week Low | $18.78 | $34.34 |
| 52 Week High | $26.51 | $95.32 |
| Indicator | PRVA | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 51.46 |
| Support Level | $21.47 | $80.52 |
| Resistance Level | $24.74 | $86.42 |
| Average True Range (ATR) | 0.90 | 3.92 |
| MACD | -0.17 | -0.17 |
| Stochastic Oscillator | 28.13 | 62.12 |
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.